Cargando…
Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy
Hoefges et al. utilized a whole-proteome peptide array approach to show that C57BL/6 mice develop a large repertoire of antibodies against linear peptide sequences of their melanoma after receiving a curative immunotherapy regimen consisting of radiation and an immunocytokine. Antibodies can play an...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996675/ https://www.ncbi.nlm.nih.gov/pubmed/36896021 http://dx.doi.org/10.1101/2023.02.24.529012 |
_version_ | 1784903096072142848 |
---|---|
author | Hoefges, A McIlwain, SJ Erbe, AK Mathers, N Xu, A Melby, D Tetreault, K Le, T Kim, K Pinapati, RS Garcia, B Patel, J Heck, M Feils, AS Tsarovsky, N Hank, JA Morris, ZS Ong, IM Sondel, PM |
author_facet | Hoefges, A McIlwain, SJ Erbe, AK Mathers, N Xu, A Melby, D Tetreault, K Le, T Kim, K Pinapati, RS Garcia, B Patel, J Heck, M Feils, AS Tsarovsky, N Hank, JA Morris, ZS Ong, IM Sondel, PM |
author_sort | Hoefges, A |
collection | PubMed |
description | Hoefges et al. utilized a whole-proteome peptide array approach to show that C57BL/6 mice develop a large repertoire of antibodies against linear peptide sequences of their melanoma after receiving a curative immunotherapy regimen consisting of radiation and an immunocytokine. Antibodies can play an important role in innate and adaptive immune responses against cancer, and in preventing infectious disease. Flow cytometry analysis of sera of immune mice that were previously cured of their melanoma through a combined immunotherapy regimen with long-term memory showed strong antibody-binding against melanoma tumor cell lines. Using a high-density whole-proteome peptide array, we assessed potential protein-targets for antibodies found in immune sera. Sera from 6 of these cured mice were analyzed with this high-density, whole-proteome peptide array to determine specific antibody-binding sites and their linear peptide sequence. We identified thousands of peptides that were targeted by 2 or more of these 6 mice and exhibited strong antibody binding only by immune, not naive sera. Confirmatory studies were done to validate these results using 2 separate ELISA-based systems. To the best of our knowledge, this is the first study of the “immunome” of protein-based epitopes that are recognized by immune sera from mice cured of cancer via immunotherapy. |
format | Online Article Text |
id | pubmed-9996675 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-99966752023-03-10 Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy Hoefges, A McIlwain, SJ Erbe, AK Mathers, N Xu, A Melby, D Tetreault, K Le, T Kim, K Pinapati, RS Garcia, B Patel, J Heck, M Feils, AS Tsarovsky, N Hank, JA Morris, ZS Ong, IM Sondel, PM bioRxiv Article Hoefges et al. utilized a whole-proteome peptide array approach to show that C57BL/6 mice develop a large repertoire of antibodies against linear peptide sequences of their melanoma after receiving a curative immunotherapy regimen consisting of radiation and an immunocytokine. Antibodies can play an important role in innate and adaptive immune responses against cancer, and in preventing infectious disease. Flow cytometry analysis of sera of immune mice that were previously cured of their melanoma through a combined immunotherapy regimen with long-term memory showed strong antibody-binding against melanoma tumor cell lines. Using a high-density whole-proteome peptide array, we assessed potential protein-targets for antibodies found in immune sera. Sera from 6 of these cured mice were analyzed with this high-density, whole-proteome peptide array to determine specific antibody-binding sites and their linear peptide sequence. We identified thousands of peptides that were targeted by 2 or more of these 6 mice and exhibited strong antibody binding only by immune, not naive sera. Confirmatory studies were done to validate these results using 2 separate ELISA-based systems. To the best of our knowledge, this is the first study of the “immunome” of protein-based epitopes that are recognized by immune sera from mice cured of cancer via immunotherapy. Cold Spring Harbor Laboratory 2023-04-28 /pmc/articles/PMC9996675/ /pubmed/36896021 http://dx.doi.org/10.1101/2023.02.24.529012 Text en https://creativecommons.org/licenses/by-nd/4.0/This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Hoefges, A McIlwain, SJ Erbe, AK Mathers, N Xu, A Melby, D Tetreault, K Le, T Kim, K Pinapati, RS Garcia, B Patel, J Heck, M Feils, AS Tsarovsky, N Hank, JA Morris, ZS Ong, IM Sondel, PM Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy |
title | Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy |
title_full | Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy |
title_fullStr | Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy |
title_full_unstemmed | Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy |
title_short | Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy |
title_sort | antibody landscape of c57bl/6 mice cured of b78 melanoma via immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996675/ https://www.ncbi.nlm.nih.gov/pubmed/36896021 http://dx.doi.org/10.1101/2023.02.24.529012 |
work_keys_str_mv | AT hoefgesa antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT mcilwainsj antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT erbeak antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT mathersn antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT xua antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT melbyd antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT tetreaultk antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT let antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT kimk antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT pinapatirs antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT garciab antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT patelj antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT heckm antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT feilsas antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT tsarovskyn antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT hankja antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT morriszs antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT ongim antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy AT sondelpm antibodylandscapeofc57bl6micecuredofb78melanomaviaimmunotherapy |